Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown clinical activity in patients with germline BRCA1/2 mutation (gBRCAm)-associated breast and ovarian cancers. Accumulating evidence suggests that PARPi may have a wider application in the treatment of cancers defective in DNA damage repair pat...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: O’Sullivan, Ciara C., Moon, Dominic H., Kohn, Elise C., Lee, Jung-Min
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2014
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3937815/
https://ncbi.nlm.nih.gov/pubmed/24616882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2014.00042
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky